Chronic Renal Insufficiency Clinical Trial
Official title:
African American Study of Kidney Disease and Hypertension
The AASK is a multicenter, randomized, controlled clinical trial using a 2 × 3 factorial design to evaluate the effects of level of blood pressure control and type of anti-hypertensive medication on progression of chronic renal disease among African American men and women with chronic renal insufficiency caused by hypertension (hypertensive nephrosclerosis).
The AASK is a multicenter, randomized, controlled clinical trial using a 2 × 3 factorial design to evaluate the effects of level of blood pressure control and type of anti-hypertensive medication on progression of chronic renal disease among African American men and women with chronic renal insufficiency caused by hypertension (hypertensive nephrosclerosis). Two levels of blood pressure control were defined in terms of mean arterial pressure (MAP = 2/3 diastolic blood pressure + 1/3 systolic blood pressure). A usual goal is defined as an MAP of 102 to 107 mm Hg, and a low goal is defined as an MAP of 92 mm Hg or less. The three antihypertensive drug regimens contained either a calcium channel blocker (amlodipine), β-blocker (metoprolol; Toprol XL), or angiotensin-converting enzyme inhibitor (ramipril) as initial therapy. Progression of renal disease was measured as the rate of decline in glomerular filtration rate (GFR). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00968877 -
Vitamin D and Chronic Renal Insufficiency
|
Phase 3 | |
| Terminated |
NCT00701714 -
Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients
|
Phase 3 | |
| Completed |
NCT00998972 -
N-acetyl-cysteine (NAC) and Kidney Graft Function
|
Phase 3 | |
| Completed |
NCT00716573 -
Efficacy Study of Everolimus on Renal Function in Heart Transplant Recipients With Established Chronic Renal Failure
|
Phase 4 | |
| Recruiting |
NCT04334707 -
Kidney Precision Medicine Project
|
||
| Completed |
NCT02203084 -
Social Determinants in Chronic Disease in British Columbia
|
N/A | |
| Recruiting |
NCT02147782 -
Clinical Observation on Bone Metabolism Induced by Chronic Renal Insufficiency
|
||
| Completed |
NCT01029002 -
The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease
|
Phase 3 | |
| Completed |
NCT00742716 -
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
|
Phase 2 | |
| Completed |
NCT00095056 -
An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)
|
Phase 3 | |
| Completed |
NCT00223548 -
MESNA for Prevention of Acute Deterioration of Renal Function Following Contrast Agent Application
|
Phase 2 | |
| Completed |
NCT01574157 -
Investigations of the Optimum Serum Bicarbonate Level in Renal Disease.
|
N/A | |
| Active, not recruiting |
NCT02751099 -
Bone and Cardiovascular Disease After Kidney Transplant
|
||
| Recruiting |
NCT02002585 -
Renal Protection Using Sympathetic Denervation in Patients With Chronic Kidney Disease
|
Phase 2 | |
| Completed |
NCT01252810 -
Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure
|
Phase 2 | |
| Completed |
NCT01245374 -
Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents
|
Phase 4 | |
| Completed |
NCT00792857 -
Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)
|
Phase 1 | |
| Completed |
NCT00888069 -
Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects
|
Phase 1 | |
| Completed |
NCT00369733 -
STAAR-3 Clinical Study
|
Phase 4 | |
| Recruiting |
NCT06362759 -
A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP
|
Phase 2 |